0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study

      research-article
      1 , 2 , 1 , 2 , 3 , 4 , 3 , 5 , 6 , 7 , 1 , 2 , 8 , 1 , 2 , 1 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 4 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26
      Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
      Oxford University Press
      tuberculosis, contacts, drug resistance, prophylaxis, preventive therapy

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Household contacts (HHCs) of individuals with multidrug-resistant tuberculosis (MDR-TB) are at high risk of infection and subsequent disease. There is limited evidence on the willingness of MDR-TB HHCs to take MDR-TB preventive therapy (MDR TPT) to decrease their risk of TB disease.

          Methods

          In this cross-sectional study of HHCs of MDR-TB and rifampicin-resistant tuberculosis (RR-TB) index cases from 16 clinical research sites in 8 countries, enrollees were interviewed to assess willingness to take a hypothetical, newly developed MDR TPT if offered. To identify factors associated with willingness to take MDR TPT, a marginal logistic model was fitted using generalized estimating equations to account for household-level clustering.

          Results

          From 278 MDR-TB/RR-TB index case households, 743 HHCs were enrolled; the median age of HHCs was 33 (interquartile range, 22–49) years, and 62% were women. HHC willingness to take hypothetical MDR TPT was high (79%) and remained high even with the potential for mild side effects (70%). Increased willingness was significantly associated with current employment or schooling (adjusted odds ratio [aOR], 1.83 [95% confidence interval {CI}, 1.07–3.13]), appropriate TB-related knowledge (aOR, 2.22 [95% CI, 1.23–3.99]), confidence in taking MDR TPT (aOR, 7.16 [95% CI, 3.33–15.42]), and being comfortable telling others about taking MDR TPT (aOR, 2.29 [95% CI, 1.29–4.06]).

          Conclusions

          The high percentage of HHCs of MDR-TB/RR-TB index cases willing to take hypothetical MDR TPT provides important evidence for the potential uptake of effective MDR TPT when implemented. Identified HHC-level variables associated with willingness may inform education and counseling efforts to increase HHC confidence in and uptake of MDR TPT.

          Abstract

          In this multi-site, cross-sectional study of household contacts (HHCs) of multidrug-resistant tuberculosis (MDR-TB) index cases, a high percentage of HHCs reported willingness to take hypothetical newly developed MDR TB preventive therapy. Identified factors associated with willingness may inform counseling efforts.

          Related collections

          Author and article information

          Journal
          Clin Infect Dis
          Clin. Infect. Dis
          cid
          Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
          Oxford University Press (US )
          1058-4838
          1537-6591
          01 February 2020
          28 March 2019
          28 March 2020
          : 70
          : 3
          : 436-445
          Affiliations
          [1 ] Byramjee Jeejeebhoy Government Medical College Clinical Trials Unit , Pune, India
          [2 ] Johns Hopkins Medical Institutions , Baltimore, Maryland
          [3 ] Harvard T. H. Chan School of Public Health , Boston, Massachusetts
          [4 ] Desmond Tutu TB Centre, Stellenbosch University , Tygerberg, South Africa
          [5 ] Social and Scientific Systems, Inc , Silver Springs, Maryland
          [6 ] Frontier Science and Technology Research Foundation , Amherst, New York
          [7 ] National Institutes of Health , Bethesda, Maryland
          [8 ] University of Cape Town Lung Institute , Mowbray, South Africa
          [9 ] Barranco Clinical Research Site
          [10 ] Asociación Civil Impacta Salud y Educación, San Miguel Clinical Research Site , Lima, Peru
          [11 ] Chennai Antiviral Research and Treatment Clinical Research Site , India
          [12 ] TASK Applied Science Clinical Research Site , Bellville
          [13 ] University of the Witwatersrand Helen Joseph Hospital , Johannesburg
          [14 ] South African Tuberculosis Vaccine Initiative , Cape Town, South Africa
          [15 ] GHESKIO Centers–Institute of Infectious Diseases and Reproductive Health , Port-au-Prince, Haiti
          [16 ] Gaborone Clinical Research Site , Botswana
          [17 ] Program for HIV Prevention and Treatment-Chiangrai Prachanukroh Hospital , Thailand
          [18 ] Perinatal HIV Research Unit, University of the Witwatersrand , Johannesburg
          [19 ] Durban International Clinical Research Site , South Africa
          [20 ] Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz , Rio de Janeiro, Brazil
          [21 ] Kenya Medical Research Institute , Kisumu
          [22 ] University of Nebraska Medical Center , Omaha
          [23 ] Aurum Institute
          [24 ] School of Public Health, University of the Witwatersrand , Johannesburg
          [25 ] Advancing Care and Treatment for TB/HIV, South African Medical Research Council , Parktown, South Africa
          [26 ] Centers for Disease Control and Prevention , Atlanta, Georgia
          Author notes

          N. S. and M. M. contributed equally to this work.

          Correspondence: N. Suryavanshi, Byramjee Jeejeebhoy Government Medical College Clinical Trials Unit, Jai Prakash Narayan Road, Pune, India 411001 ( nishisuryavanshi@ 123456hotmail.com ).
          Author information
          http://orcid.org/0000-0001-7036-2718
          Article
          PMC7188234 PMC7188234 7188234 ciz254
          10.1093/cid/ciz254
          7188234
          30919881
          ddbc346a-7edb-424f-82da-669cd2cd5c10
          © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

          This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

          History
          : 16 October 2018
          : 26 March 2019
          : 26 March 2019
          Page count
          Pages: 10
          Funding
          Funded by: National Institute of Allergy and Infectious Diseases, DOI 10.13039/100000060;
          Funded by: National Institutes of Health, DOI 10.13039/100000002;
          Award ID: UM1AI068634
          Award ID: UM1AI068636
          Award ID: UM1AI106701
          Funded by: Eunice Kennedy Shriver National Institute of Child Health and Human Development, DOI 10.13039/100009633;
          Funded by: National Institute of Mental Health, DOI 10.13039/100000025;
          Award ID: UM1AI068632
          Award ID: UM1AI068616
          Award ID: UM1AI106716
          Funded by: National Institute of General Medical Sciences, DOI 10.13039/100000057;
          Award ID: 5T32GM007309-43
          Funded by: Fogarty International Center, DOI 10.13039/100000061;
          Award ID: D43TW009340
          Funded by: National Institute of Neurological Disorders and Stroke, DOI 10.13039/100000065;
          Funded by: National Heart, Lung, and Blood Institute, DOI 10.13039/100000050;
          Funded by: National Institute of Environmental Health Sciences, DOI 10.13039/100000066;
          Categories
          Articles and Commentaries

          preventive therapy,tuberculosis,contacts,drug resistance,prophylaxis

          Comments

          Comment on this article